Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra Inc. (NYSE: PEN) delivers innovative medical technologies transforming vascular intervention worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's thrombectomy systems, regulatory milestones, and market strategies.
Access real-time press releases covering product approvals, clinical trial results, and financial performance. Our curated news collection includes analysis of Penumbra's neurovascular devices, partnership announcements, and global expansion initiatives.
Key updates feature developments in computer-assisted vacuum thrombectomy (CAVT) technology, peripheral vascular solutions, and quality improvement initiatives. Stay informed about Penumbra's progress in addressing ischemic stroke, pulmonary embolism, and other critical vascular conditions.
Bookmark this page for verified updates on Penumbra's operational achievements and industry leadership. Check regularly for insights into how the company's medical devices continue shaping modern interventional therapies across 100+ countries.
Penumbra, Inc. (NYSE: PEN) has announced a partnership with RapidAI to enhance clinical decision-making for pulmonary embolism (PE) diagnosis. This collaboration aims to develop AI-driven modules that streamline triage and improve the interpretation of CT scans. The initiative is timely, considering the challenges posed by the COVID-19 pandemic. Penumbra's Indigo® System, recently launched for blood clot removal, aligns with its commitment to addressing unmet clinical needs. The partnership is expected to increase awareness and treatment options for PE, a critical healthcare issue.
Penumbra, Inc. (NYSE: PEN) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 PM ET (10:30 AM PT). The event will showcase the company's innovative healthcare solutions. Interested parties can access a webcast of the presentation through the company's website, available for two weeks post-event. Penumbra specializes in designing and market-leading products for challenging medical conditions, primarily serving U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) reported third-quarter 2020 financials, revealing a revenue increase of 8.3% to $151.1 million compared to the same period in 2019. US revenue surged 22% to $109.7 million. However, neuro product sales declined by 8.8%, totaling $75.9 million, while vascular product sales rose 33.6% to $75.2 million. Operating loss stood at $20.2 million, impacted by one-time personnel expenses related to the Lightning product launch. The ongoing COVID-19 pandemic continues to create uncertainty in business performance.
Penumbra, Inc. (NYSE: PEN) will hold a conference call on October 28, 2020, at 4:30 PM ET to discuss its Q3 2020 financial results. The call will occur after market close, and a press release with the financial results will be available at that time. This initiative highlights Penumbra's support for democracy by designating Election Day 2020 as a paid holiday for U.S. employees. Investors can access the call by phone or via a webcast on the company’s website.
Penumbra, Inc. (NYSE: PEN) announced that its management will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 10:15 AM EDT. The event will be accessible via a webcast on the company's investor website, available for two weeks post-event. Penumbra, headquartered in Alameda, California, specializes in innovative healthcare solutions, selling products to hospitals in the U.S., Europe, Canada, and Australia, among other regions.
Penumbra, Inc. (NYSE: PEN) announced its participation in the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 3:20 PM EDT. The presentation will showcase Penumbra's innovative healthcare solutions.
Investors can access the webcast on the company's website and it will be available for two weeks after the event. Penumbra is focused on developing and marketing advanced therapies for medical conditions, primarily selling its products in the U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) reported a 21.7% decline in revenues to $105.1 million for Q2 2020 compared to Q2 2019. US revenue reached $78.0 million, down approximately 10% year-over-year. The company's gross profit was $64.9 million, reflecting a margin decrease to 61.8%. Total operating expenses rose to $82.6 million, leading to an operating loss of $17.6 million. The COVID-19 pandemic continues to impact business operations, and the company cannot reliably estimate future effects.
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 3:30 PM EDT. The presentation will be available via webcast through the company’s investor section on its website, accessible for two weeks post-event. Based in Alameda, California, Penumbra focuses on innovative therapies across healthcare, targeting significant medical needs and selling products mainly in the U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) has announced a conference call scheduled for August 3, 2020, at 4:30 PM ET to discuss its financial results for the second quarter of 2020. A press release detailing the financial results will be issued after market close on the same day. The conference call can be accessed by phone or via webcast on the company’s website. Penumbra is a global healthcare company focused on innovative therapies and sells its products to hospitals and healthcare providers primarily through a direct sales organization.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
